Issue 29, 2025, Issue in Progress

Development and in vitro evaluation of 1,4,7-triazacyclononane-coupled β-lactams against metallo-β-lactamase producing bacteria

Abstract

Antimicrobial resistance (AMR) is a critical global issue, particularly against β-lactam antibiotics, which comprise over 60% of prescriptions. Metallo-β-lactamases (MBLs) are especially concerning as they inactivate nearly all β-lactams, except monobactams. Unlike serine-β-lactamases (SBLs), for which inhibitors exist, there are no clinically approved MBL inhibitors; only taniborbactam is in pre-registration. This study introduces eight new MBL inhibitors (13a–f, 14a-b), designed using a 1,4,7-triazacyclononane (NO3PY) chelator linked to a β-lactam. These inhibitors restored the efficacy of meropenem, reducing its minimum inhibitory concentration (MIC) against MBL-expressing pathogens to <2 mg L−1. Time-kill assays confirmed bactericidal activity, with this series being non-toxic and highly specific, these compounds hold promising potential as MBL inhibitors.

Graphical abstract: Development and in vitro evaluation of 1,4,7-triazacyclononane-coupled β-lactams against metallo-β-lactamase producing bacteria

Supplementary files

Article information

Article type
Paper
Submitted
14 Mar 2025
Accepted
23 Jun 2025
First published
07 Jul 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 23427-23440

Development and in vitro evaluation of 1,4,7-triazacyclononane-coupled β-lactams against metallo-β-lactamase producing bacteria

M. Shungube, N. Reddy, T. Ghazi, K. B. Govender, R. Singh, A. Kajee, A. Chuturgoon, H. G. Kruger, P. I. Arvidsson, D. Tiwari, T. Govender and T. Naicker, RSC Adv., 2025, 15, 23427 DOI: 10.1039/D5RA01842K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements